{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T15:38:56Z","timestamp":1791560336483,"version":"4.3.4"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,11,14]],"date-time":"2023-11-14T00:00:00Z","timestamp":1699920000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,11,14]],"date-time":"2023-11-14T00:00:00Z","timestamp":1699920000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Patient Rep Outcomes"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>This study evaluated the content validity and psychometric properties of the Patient-Reported Outcomes Measurement Information System\u00ae (PROMIS)-Fatigue Short Form 7a (SF-7a) v1.0 scale to determine its suitability in clinical trials to assess fatigue in patients with moderately to severely active Crohn\u2019s disease (CD) and ulcerative colitis (UC).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A qualitative interview assessed patients\u2019 experience living with CD (N\u2009=\u200920) and UC (N\u2009=\u200919). The contents of the SF-7a scale were cognitively debriefed to evaluate content validity. A psychometric evaluation was performed using data from clinical trials of patients with CD (N\u2009=\u2009360) and UC (N\u2009=\u2009214). Correlations with Inflammatory Bowel Disease Questionnaire (IBDQ), Crohn\u2019s Disease Activity Index (CDAI; CD only), and Mayo score (UC only) determined validity. The Patient Global Impression of Change (PGIC) was used to evaluate reliability and responsiveness to change. Using PGIC as an anchor, a preliminary threshold for clinically meaningful change was identified to define fatigue response in both CD and UC patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>All patients reported fatigue as a common symptom. Patients confirmed SF-7a items were relevant to assessing fatigue, instructions and response options were clear, and its 7-day recall period was appropriate. Higher SF-7a scores were associated with higher disease activity (CDAI and Mayo score) and lower health-related quality of life (IBDQ), confirming known groups validity. The correlation of the SF-7a scale was higher with fatigue-related items. (r<jats:sub>s<\/jats:sub> \u2265 -0.70) than with items not directly associated with fatigue. Test-retest reliability was moderate to good (0.54\u20130.89) among patients with stable disease, and responsiveness to change in disease severity was demonstrated from baseline to Week 12. A \u22657point decrease was identified as a reasonable threshold to define clinically meaningful improvement.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The SF-7a scale is a valid, reliable, and sensitive measure of fatigue in patients with moderately to severely active IBD and can be used to evaluate treatment response.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s41687-023-00645-0","type":"journal-article","created":{"date-parts":[[2023,11,14]],"date-time":"2023-11-14T12:02:46Z","timestamp":1699963366000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Qualitative and psychometric evaluation of the PROMIS\u00ae-Fatigue SF-7a scale to assess fatigue in patients with moderately to severely active inflammatory bowel disease"],"prefix":"10.1186","volume":"7","author":[{"given":"Brian G.","family":"Feagan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William J.","family":"Sandborn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce E.","family":"Sands","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Vetter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan D.","family":"Mathias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuan-Hsiang Gary","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jewel","family":"Johanns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Germinaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7175-7834","authenticated-orcid":false,"given":"Chenglong","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,11,14]]},"reference":[{"issue":"4","key":"645_CR1","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1038\/s41575-018-0091-9","volume":"16","author":"NZ Borren","year":"2019","unstructured":"Borren NZ, van der Woude CJ, Ananthakrishnan AN (2019) Fatigue in IBD: epidemiology, pathophysiology and management. Nat Rev Gastroenterol Hepatol 16(4):247\u2013259. https:\/\/doi.org\/10.1038\/s41575-018-0091-9","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"5","key":"645_CR2","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1053\/j.gastro.2020.12.031","volume":"160","author":"D Turner","year":"2021","unstructured":"Turner D, Ricciuto A, Lewis A, D\u2019Amico F, Dhaliwal J, Griffiths AM et al (2021) STRIDE-II: an update on the selecting therapeutic targets in inflammatory bowel Disease (STRIDE) Initiative of the International Organization for the study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD. Gastroenterology 160(5):1570\u20131583. https:\/\/doi.org\/10.1053\/j.gastro.2020.12.031","journal-title":"Gastroenterology"},{"issue":"1","key":"645_CR3","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1093\/ecco-jcc\/jjv168","volume":"10","author":"JE Kreijne","year":"2016","unstructured":"Kreijne JE, Lie MR, Vogelaar L, van der Woude CJ (2016) Practical Guideline for Fatigue Management in inflammatory bowel Disease. J Crohns Colitis 10(1):105\u2013111. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjv168","journal-title":"J Crohns Colitis"},{"issue":"7","key":"645_CR4","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1002\/ibd.21530","volume":"17","author":"LP Jelsness-Jorgensen","year":"2011","unstructured":"Jelsness-Jorgensen LP, Bernklev T, Henriksen M, Torp R, Moum BA (2011) Chronic fatigue is more prevalent in patients with inflammatory bowel Disease than in healthy controls. Inflamm Bowel Dis 17(7):1564\u20131572. https:\/\/doi.org\/10.1002\/ibd.21530","journal-title":"Inflamm Bowel Dis"},{"key":"645_CR5","doi-asserted-by":"crossref","unstructured":"Sandborn WJ, Chan D, Johanns J, Lang G, Adedokun OJ, Afzali A et al (2020) The efficacy and safety of guselkumab induction therapy in patients with moderately to severely active Crohn\u2019s Disease: Week 12 interim analyses from the phase 2 GALAXI-1 study [abstract]. Virtual Meeting. United European Gastroenterology Week (UEGW)","DOI":"10.1016\/S0016-5085(21)01553-5"},{"key":"645_CR6","doi-asserted-by":"crossref","unstructured":"D\u2019Haens G, Rubin DT, Pan\u00e9s J, Gonzalez S, Chan D, Johanns J et al (2021) The effect of guselkumab induction therapy on endoscopic outcome measures in patients with moderately to severely active Crohn\u2019s Disease: Week 12 results from the phase 2 GALAXI-1 study [abstract]. Digestive Disease Week (DDW). Virtual Meeting","DOI":"10.1016\/S0016-5085(21)00960-4"},{"key":"645_CR7","doi-asserted-by":"crossref","unstructured":"Sands BE, Danese S, Andrews JM, Weisel K, Chan D, Johanns J et al (2021) The effect of guselkumab induction therapy on inflammatory biomarkers in patients with moderately to severely active Crohn\u2019s Disease: Week 12 results from the phase 2 GALAXI-1 study [abstract]. Digestive Disease Week (DDW). Virtual Meeting","DOI":"10.1016\/S0016-5085(21)01553-5"},{"key":"645_CR8","doi-asserted-by":"crossref","unstructured":"Feagan BG, Sands B, Sandborn WJ, Shipitofsky N, Marko M, Sheng S et al (2022) Efficacy and safety of combination induction therapy with guselkumab and golimumab in participants with moderately-to-severely active ulcerative colitis: Results through Week 12 of the phase 2a VEGA study. Digestive Disease Week, San Diego, CA, 21\u201324 May 2022","DOI":"10.1016\/S0016-5085(22)60515-8"},{"key":"645_CR9","doi-asserted-by":"crossref","unstructured":"Sands BE, Feagan B, Sandborn WJ, Shipitofsky N, Marko M, Sheng S et al (2022) Efficacy and safety of combination induction therapy with guselkumab and golimumab in participants with moderately-to-severely active ulcerative colitis: Results through Week 12 of a phase 2a randomized, double-blind, active-controlled, parallel-group, multicenter, proof-of-concept study. European Crohn\u2019s and Colitis Organisation (ECCO). Virtual 16\u201319 Feb 2022","DOI":"10.1093\/ecco-jcc\/jjab232.035"},{"issue":"6","key":"645_CR10","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1053\/j.gastro.2022.01.047","volume":"162","author":"WJ Sandborn","year":"2022","unstructured":"Sandborn WJ, D\u2019Haens GR, Reinisch W, Pan\u00e9s J, Chan D, Gonzalez S et al (2022) Guselkumab for the treatment of Crohn\u2019s disease: Induction results from the phase 2 GALAXI-1 study. Gastroenterology 162(6):1650\u20131664e8. https:\/\/doi.org\/10.1053\/j.gastro.2022.01.047","journal-title":"Gastroenterology"},{"key":"645_CR11","doi-asserted-by":"publisher","unstructured":"Feagan BG, Sands B, Sandborn WJ, Germinaro M, Vetter M, Shao J et al (2023) Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): A randomized, double-blind, controlled, phase 2, proof-of-concept trial. Epub ahead of print. https:\/\/doi.org\/10.1016\/S2468-1253(22)00427-7., 1 Feb 2023","DOI":"10.1016\/S2468-1253(22)00427-7"},{"key":"645_CR12","unstructured":"PROMIS (2022) [Available from: https:\/\/www.healthmeasures.net\/score-and-interpret\/interpret-scores\/promis. Accessed 14 Feb 2022"},{"issue":"3","key":"645_CR13","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1097\/00054725-200405000-00014","volume":"10","author":"AG Pallis","year":"2004","unstructured":"Pallis AG, Mouzas IA, Vlachonikolis IG (2004) The inflammatory bowel Disease questionnaire: a review of its national validation studies. Inflamm Bowel Dis 10(3):261\u2013269. https:\/\/doi.org\/10.1097\/00054725-200405000-00014","journal-title":"Inflamm Bowel Dis"},{"key":"645_CR14","unstructured":"Clinical Review Report : Adalimumab (Humira) (2016). Canadian Agency for Drugs and Technologies in Health, Ottawa (ON)"},{"key":"645_CR15","doi-asserted-by":"publisher","first-page":"653714","DOI":"10.1155\/2012\/653714","volume":"2012","author":"CS Boomershine","year":"2012","unstructured":"Boomershine CS (2012) A comprehensive evaluation of standardized assessment tools in the diagnosis of fibromyalgia and in the assessment of fibromyalgia severity. Pain Res Treat 2012:653714. https:\/\/doi.org\/10.1155\/2012\/653714","journal-title":"Pain Res Treat"},{"key":"645_CR16","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/B978-1-4377-1529-3.00021-X","volume-title":"Clinical gastrointestinal endoscopy","author":"JK Liu","year":"2012","unstructured":"Liu JK, Lichenstein GR (2012) Inflammatory bowel Disease. In: Ginsberg GG, Gostout CJ, Kochman ML, Norton ID (eds) Clinical gastrointestinal endoscopy, 2nd edn. Elsevier Saunders, St. Louis, pp 243\u2013264","edition":"2"},{"key":"645_CR17","doi-asserted-by":"publisher","first-page":"S23","DOI":"10.1097\/00005176-199904001-00003","volume":"28","author":"E Irvine","year":"1999","unstructured":"Irvine E (1999) Development and subsequent refinement of the inflammatory bowel Disease Questionnaire: a quality-of-life instrument for adult patients with inflammatory bowel Disease. J Pediatr Gastroenterol Nutr 28:S23\u2013S27. https:\/\/doi.org\/10.1097\/00005176-199904001-00003","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"645_CR18","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1111\/j.1365-2036.2008.03854.x","volume":"28","author":"EJ Irvine","year":"2008","unstructured":"Irvine EJ, Yeh C-H, Ramsey D, Stirling AL, Higgins PDR (2008) The effect of mesalazine therapy on quality of life in patients with mildly and moderately active ulcerative Colitis. Aliment Pharmacol Ther 28:1278\u20131286","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"645_CR19","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/S0016-5085(76)80163-1","volume":"70","author":"WR Best","year":"1976","unstructured":"Best WR, Becktel JM, Singleton JW, Kern F Jr (1976) Development of a crohn\u2019s disease activity index: National cooperative crohn\u2019s disease study. Gastroenterology 70(3):439\u2013444","journal-title":"Gastroenterology"},{"issue":"2","key":"645_CR20","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.jcm.2016.02.012","volume":"15","author":"TK Koo","year":"2016","unstructured":"Koo TK, Li MY (2016) A guideline of selecting and reporting intraclass correlation coefficients for reliability research. J Chiropr Med 15(2):155\u2013163. https:\/\/doi.org\/10.1016\/j.jcm.2016.02.012","journal-title":"J Chiropr Med"},{"key":"645_CR21","volume-title":"Statistical power analysis for the behavioral sciences","author":"J Cohen","year":"1988","unstructured":"Cohen J (1988) Statistical power analysis for the behavioral sciences, 2nd edn. Academic Press, New York","edition":"2"},{"issue":"11","key":"645_CR22","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1016\/0895-4356(95)00054-2","volume":"48","author":"G Stucki","year":"1995","unstructured":"Stucki G, Liang MH, Fossel AH, Katz JN (1995) Relative responsiveness of condition-specific and generic health status measures in degenerative lumbar spinal stenosis. J Clin Epidemiol 48(11):1369\u20131378. https:\/\/doi.org\/10.1016\/0895-4356(95)00054-2","journal-title":"J Clin Epidemiol"},{"issue":"8","key":"645_CR23","first-page":"889","volume":"134","author":"GH Guyatt","year":"1986","unstructured":"Guyatt GH, Bombardier C, Tugwell PX (1986) Measuring disease-specific quality of life in clinical trials. CMAJ 134(8):889\u2013895","journal-title":"CMAJ"},{"key":"645_CR24","unstructured":"Critical Path Institute (C-PATH). Using patient input to estimate clinically meaningful within-patient change at the scale score level. Presented at: 10th Annual Patient-Reported Outcome Consortium Workshop; 24\u201325 April 2019, Silver Spring, MD. Available at: https:\/\/c-path.org\/wp-content\/uploads\/2019\/05\/2019_session6_meaningfulchgfinal.pdf. Accessed 17 August 2023"},{"issue":"2","key":"645_CR25","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1111\/j.1365-2036.2010.04347.x","volume":"32","author":"DR van Langenberg","year":"2010","unstructured":"van Langenberg DR, Gibson PR (2010) Systematic review: fatigue in inflammatory bowel Disease. Aliment Pharmacol Ther 32(2):131\u2013143. https:\/\/doi.org\/10.1111\/j.1365-2036.2010.04347.x","journal-title":"Aliment Pharmacol Ther"},{"key":"645_CR26","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1111\/j.1365-2036.2011.04871.x","volume":"34","author":"A Tinsley","year":"2011","unstructured":"Tinsley A, Macklin EA, Korzenik JR, Sands BE (2011) Validation of the Functional Assessment of Chronic Illness therapy-fatigue (FACIT-F) in patients with inflammatory bowel Disease. Aliment Pharmacol Ther 34:1328\u20131336","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"645_CR27","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.jpainsymman.2003.06.003","volume":"27","author":"KD Stein","year":"2004","unstructured":"Stein KD, Jacobsen PB, Blanchard CM, Thors C (2004) Further validation of the multidimensional fatigue symptom inventory-short form. J Pain Symptom Manage 27(1):14\u201323. https:\/\/doi.org\/10.1016\/j.jpainsymman.2003.06.003","journal-title":"J Pain Symptom Manage"},{"issue":"5","key":"645_CR28","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1002\/(sici)1097-0142(19990301)85:5<1186::aid-cncr24>3.0.co;2-n","volume":"85","author":"TR Mendoza","year":"1999","unstructured":"Mendoza TR, Wang XS, Cleeland CS, Morrissey M, Johnson BA, Wendt JK et al (1999) The rapid assessment of fatigue severity in cancer patients: use of the brief fatigue inventory. Cancer 85(5):1186\u20131196. https:\/\/doi.org\/10.1002\/(sici)1097-0142(19990301)85:5%3C1186::aid-cncr24%3E3.0.co;2-n","journal-title":"Cancer"},{"issue":"3","key":"645_CR29","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/j.jpainsymman.2008.11.015","volume":"38","author":"E Pallett","year":"2009","unstructured":"Pallett E, Rentowl P, Hanning C (2009) The brief fatigue inventory: comparison of data collection using a novel audio device with conventional paper questionnaire. J Pain Symptom Manage 38(3):390\u2013400. https:\/\/doi.org\/10.1016\/j.jpainsymman.2008.11.015","journal-title":"J Pain Symptom Manage"},{"issue":"2","key":"645_CR30","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/s0885-3924(96)00274-6","volume":"13","author":"SB Yellen","year":"1997","unstructured":"Yellen SB, Cella DF, Webster K, Blendowski C, Kaplan E (1997) Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system. J Pain Symptom Manage 13(2):63\u201374. https:\/\/doi.org\/10.1016\/s0885-3924(96)00274-6","journal-title":"J Pain Symptom Manage"},{"issue":"5","key":"645_CR31","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1177\/0961203313476360","volume":"22","author":"M Kosinski","year":"2013","unstructured":"Kosinski M, Gajria K, Fernandes AW, Cella D (2013) Qualitative validation of the FACIT-fatigue scale in systemic Lupus Erythematosus. Lupus 22(5):422\u2013430. https:\/\/doi.org\/10.1177\/0961203313476360","journal-title":"Lupus"},{"key":"645_CR32","doi-asserted-by":"publisher","DOI":"10.1007\/s41669-023-00419-w","author":"EV Loftus Jr","year":"2023","unstructured":"Loftus EV Jr., Ananthakrishnan AN, Lee WJ, Gonzalez YS, Fitzgerald KA, Wallace K et al (2023) Content validity and psychometric evaluation of the functional assessment of chronic illness therapy-fatigue (FACIT-Fatigue) in patients with crohn\u2019s disease and ulcerative colitis. Pharmacoecon Open. https:\/\/doi.org\/10.1007\/s41669-023-00419-w","journal-title":"Pharmacoecon Open"},{"key":"645_CR33","unstructured":"Jakafi \u00ae (ruxolitinib) tablets. Prescribing information (2011) Incyte Corporation, Wilmington, DE"},{"key":"645_CR34","unstructured":"Patient-reported outcome measures: Use in medical product development to support labeling claims guidance for industry (2009) US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER), Center for Devices and Radiological Health (CDRH), Rockville, MD"}],"container-title":["Journal of Patient-Reported Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41687-023-00645-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41687-023-00645-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41687-023-00645-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,14]],"date-time":"2023-11-14T12:02:53Z","timestamp":1699963373000},"score":1,"resource":{"primary":{"URL":"https:\/\/jpro.springeropen.com\/articles\/10.1186\/s41687-023-00645-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,14]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["645"],"URL":"https:\/\/doi.org\/10.1186\/s41687-023-00645-0","relation":{},"ISSN":["2509-8020"],"issn-type":[{"value":"2509-8020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,14]]},"assertion":[{"value":"13 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol for the qualitative research and informed consent forms were reviewed and approved by an independent scientific review committee prior to the start of the study. Similarly, the study protocols for the GALAXI and VEGA studies were approved by the Institutional Review Board or Independent Ethics Committee at each participating investigative center. All patients provided written informed consent prior to participating in the qualitative interview and prior to enrollment in the GALAXI and VEGA trials.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors have reviewed the final manuscript and provided their consent for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"BGF received grant\/research support from AbbVie Inc, Amgen Inc, AstraZeneca\/MedImmune Ltd, Atlantic Pharmaceuticals Ltd, Boehringer Ingelheim, Celgene Corporation, Celltech, Genentech Inc\/Hoffmann-La Roche Ltd, Gilead Sciences Inc, GlaxoSmithKline (GSK), Janssen Research & Development LLC, Pfizer Inc, Receptos Inc\/Celgene International, Sanofi, Santarus Inc, Takeda Development Center Americas Inc, Tillotts Pharma AG, and UCB; was a consultant for Abbott\/AbbVie, AdMIRx Inc, Akebia Therapeutics, Allergan, Amgen, Applied Molecular Transport Inc, Aptevo Therapeutics, Asta Pharma, AstraZeneca, Atlantic Pharma, Avir Pharma, Biogen Idec, BioMx Israel, Boehringer Ingelheim, Boston Pharmaceuticals, Bristol-Myers Squibb, Calypso Biotech, Celgene, Elan\/Biogen, EnGene, Ferring Pharma, Genentech\/Roche, Galapagos, Galen\/Atlantica, GiCare Pharma, Gilead, Gossamer Pharma, GSK, Inception IBD Inc, Intact Therapeutics, Johnson & Johnson\/Janssen, Kyowa Kakko Kirin Co Ltd, Lexicon, Lilly, Lycera BioTech, Merck, Mesoblast Pharma, Millennium, Nestle, Nextbiotix, Novonordisk, ParImmune, Parvus Therapeutics Inc, Pfizer Inc, Prometheus Therapeutics and Diagnostics, Progenity, Protagonist, Qu Biologics, Rebiotix, Receptos, Salix Pharma, Shire, Sienna Biologics, Sigmoid Pharma, Sterna Biologicals, Synergy Pharma Inc, Takeda, Teva Pharma, TiGenix, Tillotts, UCB Pharma, Vertex Pharma, Vivelix Pharma, VHsquared Ltd, and Zyngenia; was a member of the speakers bureau for Abbott\/AbbVie, Johnson & Johnson\/Janssen, Lilly, Takeda, Tillotts, and UCB Pharma; was a member of the scientific advisory board for Abbott\/AbbVie, Allergan, Amgen, AstraZeneca, Atlantic Pharma, Avaxia Biologics Inc, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Centocor Inc, Elan\/Biogen, Galapagos, Genentech\/Roche, Johnson & Johnson\/Janssen, Merck, Nestle, Novartis, Novonordisk, Pfizer Inc, Prometheus Laboratories, Protagonist, Salix Pharma, Sterna Biologicals, Takeda, Teva, TiGenix, Tillotts Pharma AG, and UCB Pharma; and is a Senior Scientific Officer - Robarts Clinical Trials Inc.WJS reports research grants from Abbvie, Abivax, Arena Pharmaceuticals, Boehringer Ingelheim, Bristol-Meyers Squibb, Genentech\/Roche, Gilead Sciences, Inc., GSK, Janssen, Lilly, Pfizer, Prometheus Laboratories, Seres Therapeutics, Shire Pharmaceuticals, Takeda, Theravance Biopharma; consulting fees from Abbvie, Abivax, Alfasigma, Alimentiv (previously Robarts Clinical Trials, owned by Alimentiv Health Trust), Allakos, Amgen, Arena Pharmaceuticals, AstraZeneca, Atlantic Pharmaceuticals, Beigene, Boehringer Ingelheim, Bristol-Meyers Squibb, Celltrion, Clostrabio, Forbion, Galapagos, Genentech\/Roche, GSK, Gossamer Bio, Index Pharmaceuticals, Iota Biosciences, Janssen, Lilly, Morphic Therapeutics, Novartis, Oppilan Pharma (now Ventyx Biosciences), Pfizer, Pharm Olam, Polpharm, Progenity, Prometheus Biosciences, Protagonist Therapeutics, PTM Therapeutics, Seres Therapeutics, Shoreline Biosciences, Sublimity Therapeutics, Surrozen, Takeda, Theravance Biopharma, Vedanta Biosciences, Ventyx Biosciences, Vimalan Biosciences, Vivreon Gastrosciences, Xencor, Zealand Pharmaceuticals; stock or stock options from Allakos, BeiGene, Gossamer Bio, Oppilan Pharma (now Ventyx Biosciences), Progenity, Prometheus Biosciences, Prometheus Laboratories, Protagonist Therapeutics, Shoreline Biosciences, Ventyx Biosciences, Vimalan Biosciences, Vivreon Gastrosciences; and employee at Shoreline Biosciences and Ventyx Biosciences. Spouse: Iveric Bio - consultant, stock options; Progenity - stock; Oppilan Pharma (now Ventyx Biosciences) - stock; Prometheus Biosciences - employee, stock, stock options; Prometheus Laboratories - stock, stock options, consultant; Ventyx Biosciences - stock, stock options; Vimalan Biosciences - stock, stock options.BES reports grants, personal fees, and other from Abivax during the conduct of the study; personal fees from Abbvie; personal fees from Alimentiv (previously Robarts Clinical Trials; owned by Alimentiv Health Trust); personal fees from Amgen; personal fees and other from Arena Pharmaceuticals; personal fees from AstraZeneca; personal fees from Bausch Health (Salix Pharmaceuticals); personal fees from Boehringer Ingelheim; personal fees from Boston Pharmaceuticals; personal fees and other from Bristol-Myers Squibb; personal fees and other from Celgene; personal fees from Celltrion; personal fees from Clostrabio; personal fees from Equillium; personal fees from Galapagos; personal fees from Genentech\/Roche; personal fees from Gilead Sciences; personal fees from GSK; personal fees from Gossamer Bio; personal fees from Immunic; personal fees from Index Pharmaceuticals; personal fees from Inotrem; grants, personal fees, and other from Janssen; grants, personal fees, and other from Lilly; personal fees from Morphic Therapeutics; personal fees from Novartis; personal fees from Oppilan Pharma (acquired by Ventyx Biosciences); personal fees from Otuska; grants, personal fees, and other from Pfizer; personal fees from Progenity; personal fees from Prometheus Biosciences; personal fees from Prometheus Laboratories; personal fees from Protagonists Therapeutics; personal fees from Seres Therapeutics; personal fees from Shire Pharmaceuticals; personal fees from Surrozen; grants, personal fees, and other from Takeda; grants and personal fees from Theravance Biopharma; personal fees from Teva; personal fees from UCB; personal fees from Vedanta Biosciences; personal fees and other from Ventyx Biosciences; personal fees from Vivelix Pharmaceuticals; personal fees from Ironwood Pharmaceuticals; personal fees from OSE Immunotherapeutics; personal fees from Redhill Biopharma; personal fees from Target RWE; personal fees from Bacainn Therapeutics; personal fees from Capella Bioscience; personal fees from Palatin Technologies; personal fees from Rheos Medicines; personal fees from USWM Enterprises; personal fees from Viela Bio; personal fees from Artugen Therapeutics; personal fees from Calibr; personal fees from Entera; personal fees from Evommune; personal fees from Innovation Pharmaceuticals; personal fees from Kaleido; personal fees from Merck; personal fees from MRM Health; personal fees from Q32 Bio; personal fees from Sun Pharma; personal fees from TLL Pharmaceutical; and other from Vivante Health outside the submitted work.SDM is an employee at Health Outcomes Solutions, which received research funding from Janssen Pharmaceuticals for conducting the qualitative research portion of this study.YL (at the time study was conducted), MV, K-HGH, JJ, MG, and CH are employees of Janssen Research & Development, LLC and own stock\/stock options.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"115"}}